Silence Therapeutics reports durable phlebotomy reduction and QoL gains from Phase 1 divesiran study at EHA 2026

Silence Therapeutics plc

21 PV patients: 5 phlebotomies during active treatment vs 80 in prior 6 months; only 4 in 16-week follow-up.
Median time to first phlebotomy was 287 days among 14 evaluable patients.
Majority had improved MPN-10 symptom scores through Week 34, indicating better quality of life.
Phase 2 SANRECO (Q6W and Q12W dosing) topline results expected August 2026.
Divesiran well tolerated; mild injection-site reactions, no treatment-related SAEs or discontinuations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.